Ubiquitin-dependent degradation of p73 is inhibited by PML

被引:102
作者
Bernassola, F
Salomoni, P
Oberst, A
Di Como, CJ
Pagano, M
Melino, G
Pandolfi, PP
机构
[1] Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[3] Univ Roma Tor Vergata, Dept Expt Med, IRCCS Biochem Lab, IDI, I-00139 Rome, Italy
[4] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA
[5] Univ Leicester, Med Res Council, Toxicol Unit, Leicester LE1 9HN, Leics, England
基金
英国医学研究理事会;
关键词
ubiquitinylation; acetylation; nuclear body; transcription; apoptosis;
D O I
10.1084/jem.20031943
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
p73 has been identified recently as a structural and functional homologue of the tumor suppressor p53. Here, we report that p73 stability is directly regulated by the ubiquitin-proteasome pathway. Furthermore, we show that the promyelocytic leukemia (PML) protein modulates p73 half-life by inhibiting its degradation in a PML-nuclear body (NB)-dependent manner. p38 mitogen-activated protein kinase-mediated phosphorylation of p73 is required for p73 recruitment into the PML-NB and subsequent PML-dependent p73 stabilization. We find that p300-mediated acetylation of p73 protects it against ubiquitinylation and that PML regulates p73 stability by positively modulating its acetylation levels. As a result, PML potentiates p73 transcriptional and proapoptotic activities that are markedly impaired in Pml(-/-) primary cells. Our findings demonstrate that PML plays a crucial role in modulating p73 function, thus providing further insights on the molecular network for tumor suppression.
引用
收藏
页码:1545 / 1557
页数:13
相关论文
共 59 条
[1]  
Agami R, 1999, NATURE, V399, P809
[2]   Mdm2 binds p73α without targeting degradation [J].
Bálint, E ;
Bates, S ;
Vousden, KH .
ONCOGENE, 1999, 18 (27) :3923-3929
[3]   p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis [J].
Bergamaschi, D ;
Gasco, M ;
Hiller, L ;
Sullivan, A ;
Syed, N ;
Trigiante, G ;
Yulug, I ;
Merlano, M ;
Numico, G ;
Comino, A ;
Attard, M ;
Reelfs, O ;
Gusterson, B ;
Bell, AK ;
Heath, V ;
Tavassoli, M ;
Farrell, PJ ;
Smith, P ;
Lu, X ;
Crook, T .
CANCER CELL, 2003, 3 (04) :387-402
[4]  
BERNARDI R, 2002, AM SOC HEMATOLOGY, V100, P107
[5]   Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation [J].
Bloom, J ;
Amador, V ;
Bartolini, F ;
DeMartino, G ;
Pagano, M .
CELL, 2003, 115 (01) :71-82
[6]   Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients [J].
Casciano, I ;
Mazzocco, K ;
Boni, L ;
Pagnan, G ;
Banelli, B ;
Allemanni, G ;
Ponzoni, M ;
Tonini, GP ;
Romani, M .
CELL DEATH AND DIFFERENTIATION, 2002, 9 (03) :246-251
[7]  
Corn PG, 1999, CANCER RES, V59, P3352
[8]   DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes [J].
Costanzo, A ;
Merlo, P ;
Pediconi, N ;
Fulco, M ;
Sartorelli, V ;
Cole, PA ;
Fontemaggi, G ;
Fanciulli, M ;
Schiltz, L ;
Blandino, G ;
Balsano, C ;
Levrero, M .
MOLECULAR CELL, 2002, 9 (01) :175-186
[9]   Induction of neuronal differentiation by p73 in a neuroblastoma cell line [J].
De Laurenzi, V ;
Raschellá, G ;
Barcaroli, D ;
Annicchiarico-Petruzzelli, M ;
Ranalli, M ;
Catani, MV ;
Tanno, B ;
Costanzo, A ;
Levrero, M ;
Melino, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (20) :15226-15231
[10]   Two new p73 splice variants, γ and δ, with different transcriptional activity [J].
De Laurenzi, V ;
Costanzo, A ;
Barcaroli, D ;
Terrinoni, A ;
Falco, M ;
Annicchiarico-Petruzzeli, M ;
Levrero, M ;
Melino, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (09) :1763-1768